Industry Trend Analysis - Single Tablet Potential Gives Jansen Edge In HIV Expansion - MAR 2017


BMI View: As the first single tablet regimen , rilpivirine and dolutegravir will have a key edge in the HIV market. Not taking multiple tablets has a noticeable compliance advantage , and allow s Jans s en Sciences to establish itself in the market. HIV remains a serious threat to global health , and expanding and simplifying anti-viral therapies is a key goal to bring HIV and AIDS under control globally.

Jans s en Sciences ( Johnson & Johnson) has announced the positive results from the first phase of its investigational Phase III studies combining Janssen's rilpivirine and ViiV Healthcare's dolutegravir in HIV. The two-drug, single tablet trial is the first of its kind and has met its primary endpoint at week 48. HIV remains a pressing concern across the developed world and is still a crisis in Africa. Simplifying and streamlining treatment and control remains a vital goal for drug development.

Non-Inferiority Will Allow For Easy Uptake

This article is part of our Western Europe coverage. To access this article subscribe now or sign up for free trial